Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency.

Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohler M, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex JF, O'Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M.

ERJ Open Res. 2020 Mar 2;6(1). pii: 00181-2019. doi: 10.1183/23120541.00181-2019. eCollection 2020 Jan.

2.

Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients.

Valipour A, Tamm M, Kociánová J, Bayer V, Sanzharovskaya M, Medvedchikov A, Haaksma-Herczegh M, Mucsi J, Fridlender Z, Toma C, Belevskiy A, Matula B, Šorli J.

Int J Chron Obstruct Pulmon Dis. 2019 Oct 11;14:2343-2354. doi: 10.2147/COPD.S204388. eCollection 2019.

3.

In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients.

Heeke S, Benzaquen J, Long-Mira E, Audelan B, Lespinet V, Bordone O, Lalvée S, Zahaf K, Poudenx M, Humbert O, Montaudié H, Dugourd PM, Chassang M, Passeron T, Delingette H, Marquette CH, Hofman V, Stenzinger A, Ilié M, Hofman P.

Cancers (Basel). 2019 Aug 29;11(9). pii: E1271. doi: 10.3390/cancers11091271.

4.

The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!

Hoeper MM, Humbert M.

Eur Respir J. 2019 Mar 28;53(3). pii: 1900038. doi: 10.1183/13993003.00038-2019. Print 2019 Mar. No abstract available.

PMID:
30923177
5.

Chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: to screen or not to screen?

Hoeper MM.

Eur Respir J. 2018 Apr 4;51(4). pii: 1800440. doi: 10.1183/13993003.00440-2018. Print 2018 Apr. No abstract available.

6.

Risk assessment in pulmonary arterial hypertension.

Hoeper MM, Pittrow D, Opitz C, Gibbs JSR, Rosenkranz S, Grünig E, Olsson KM, Huscher D.

Eur Respir J. 2018 Mar 29;51(3). pii: 1702606. doi: 10.1183/13993003.02606-2017. Print 2018 Mar. No abstract available.

7.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. Erratum in: J Clin Oncol. 2018 Feb 10;36(5):521.

PMID:
28976790
8.

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.

Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, Naeije R, Jansa P, Rosenkranz S, Scelsi L, Grünig E, Vizza CD, Chang M, Colorado P, Meier C, Busse D, Benza RL.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602425. doi: 10.1183/13993003.02425-2016. Print 2017 Sep.

9.

Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.

Halank M, Hoeper MM, Ghofrani HA, Meyer FJ, Stähler G, Behr J, Ewert R, Fletcher M, Colorado P, Nikkho S, Grimminger F.

Respir Med. 2017 Jul;128:50-56. doi: 10.1016/j.rmed.2017.05.008. Epub 2017 May 16.

Supplemental Content

Loading ...
Support Center